{"id":"W3161195108","doi":"10.1016/j.ejca.2021.04.004","title":"Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Health Services; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Calgary","funders":"Genentech; Eisai; U.S. Department of Defense; Exelixis; Congressionally Directed Medical Research Programs; Gateway for Cancer Research; Astellas Pharma; Ariad Pharmaceuticals; Bristol-Myers Squibb; Ipsen; Novartis; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Clinical trial; Clinical Oncology; Intensive care medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00319986,0.000286666,0.00199701,0.0001003879,0.00006887169,0.00003311364,0.0001627791,0.00005115953,0.0002577702],"category_scores_gemma":[0.001485667,0.0001585894,0.0004940813,0.0001490127,0.0001873121,0.00009738534,0.00005239496,0.0001801892,0.000002394736],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002300143,"about_ca_system_score_gemma":0.0007188967,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001270277,"about_ca_topic_score_gemma":0.00005092154,"domain_scores_codex":[0.995365,0.001409278,0.002095032,0.0003154146,0.0005365927,0.0002786614],"domain_scores_gemma":[0.9947369,0.0007752191,0.001809114,0.0003782047,0.00205681,0.0002437804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02961057,0.00164875,0.9476057,0.0002471215,0.002754316,0.001426867,0.0005857968,0.00006837221,0.002536309,0.000004049951,0.005541596,0.00797052],"study_design_scores_gemma":[0.02407211,0.01006334,0.9348272,0.0007269637,0.001729395,0.0000737355,0.0001011576,0.000006714645,0.0210089,0.000005045156,0.007225689,0.0001597395],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952988,0.001620007,0.0001655576,0.001258534,0.0003413888,0.000616447,0.0001625857,0.000009104238,0.0005275664],"genre_scores_gemma":[0.996125,0.0007816525,0.001748598,0.0004297864,0.0003233748,0.00001034062,0.00002434996,0.00006087496,0.0004960243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01847259,"threshold_uncertainty_score":0.6467088,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1448300445939579,"score_gpt":0.4509421169423179,"score_spread":0.30611207234836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}